Short Interest in Valneva SE (NASDAQ:VALN) Declines By 22.9%

Valneva SE (NASDAQ:VALN) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 59,700 shares, a decline of 22.9% from the June 30th total of 77,400 shares. Based on an average daily volume of 11,100 shares, the short-interest ratio is presently 5.4 days. Approximately 0.1% of the company’s shares are sold short.

Valneva Stock Performance

NASDAQ:VALN remained flat at $7.25 during trading hours on Friday. 1,907 shares of the company’s stock traded hands, compared to its average volume of 5,476. The firm has a 50 day moving average price of $7.77 and a 200 day moving average price of $7.90. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64. The stock has a market cap of $504.89 million, a P/E ratio of -17.68 and a beta of 2.20. Valneva has a 1 year low of $6.58 and a 1 year high of $15.28.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.12. The business had revenue of $35.56 million during the quarter, compared to analysts’ expectations of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. On average, sell-side analysts anticipate that Valneva will post -0.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC raised its position in Valneva SE (NASDAQ:VALN) by 42.3% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 88,252 shares of the company’s stock after acquiring an additional 26,248 shares during the period. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 as of its most recent filing with the SEC. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Valneva in a research note on Monday, July 22nd.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.